D-0159-2026 Class II Ongoing
FDA drug recall D-0159-2026 was initiated by Zydus Pharmaceuticals (USA) Inc on Oct 23, 2025 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules. The recall status is ongoing. Affected quantity: 36,624 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 26, 2025
- Initiation Date
- Oct 23, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 36,624 bottles
Product description
Bromocriptine Mesylate Capsules, USP, 5 mg, 30 Capsules per bottle, Rx Only. Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India. Distributed by: Zydus Pharmaceuticals, Pennington, NJ 08534. NDC 68382-110-06
Reason for recall
Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules.
Distribution pattern
Nationwide in the USA
Code information
Lot #: M313934, M313935, M315615, Exp. Date Nov 2025; M316809 , Exp. Date Dec-25; M405765, M405763, M405764, Exp. Date Apr-26; M414999, M414241, M414307, M414305, Exp. Date Oct-26
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0159-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026